DUBLIN--(BUSINESS WIRE)--The "Global C-reactive Protein Testing Market - Segmented by Assay Type, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global C-reactive protein (CRP) testing market is expected to register a CAGR of nearly 1.5% during the forecast period of 2018-2023.
C-reactive protein is one of the common test parameters used to assess, diagnose, and prognose inflammatory diseases in clinical practice. The concomitant occurrence of multiple stimuli of inflammation and influence of factors other than inflammation like smoking, obesity, and physical stress, reduce the specificity of CRP.
The lack of public awareness regarding CRP testing is one of the primary hinderances for the C-reactive testing market. According to a published article of 2016 in Journal of Medicine, Radiology, Pathology & Surgery, in emerging countries such as India, more than 50% of population suffering from diabetes are unaware of the blood tests including CRP tests, for the early diagnosis of diabetes.
The United States is one of the primary markets for critical care diagnostics, and it is expected to dominate the market in the forecast period due to the presence of established multinational players such as LabCorp with multiple manufacturing plants, technological advancements, and well-established healthcare infrastructure.
Companies Mentioned
- Abaxis
- Abbott
- Danaher
- Hoffmann-La Roche Ltd.
- Laboratory Corporation Of America Holdings
- Merck Kgaa
- Quest Diagnostics
- Randox Laboratories Ltd.
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Market Dynamics
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
11. Disclaimer
For more information about this report visit https://www.researchandmarkets.com/research/8tkc32/global_creactive?w=4
